NM002

About NovaBiotics

NovaBiotics is an innovative, privately-held biotech group with a bifurcated strategy. Its advanced Pharma pipeline, featuring host-directed anti-infectives like NM001 and NM002, targets significant unmet needs in cystic fibrosis, respiratory infections, and mycobacterial diseases like TB. Concurrently, its commercial Consumer Health arm generates early revenue through Tinexyl PRO, a professional-grade nail health product, providing a non-dilutive funding stream and market validation for its platform. The company is led by founder and CEO Dr. Deborah O'Neil and maintains strategic collaborations with academic and commercial partners.

Therapeutic Areas